Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Provided By GlobeNewswire
Last update: Oct 2, 2025
ANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophrenia
Encouraging trends observed in biomarkers support continued development
Read more at globenewswire.com
